Cargando…
Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial
INTRODUCTION: For idiopathic inflammatory myopathies (IIM) (‘myositis’) standard initial treatment is high-dosed glucocorticoids, which results in relatively slow improvement of muscle strength. Early immunosuppression or modulation by intensive treatment (‘hit-early, hit-hard’) may induce faster re...
Autores principales: | Kamperman, Renske G, Bogaards, Johannes A, Evers, Sanne W, Walter, Hannah A W, de Visser, Marianne, de Borgie, Corianne, Colen - de Koning, Jantine C A, Verhamme, Camiel, Maas, Mario, Eftimov, Filip, van Schaik, Ivo N, van der Kooi, Anneke J, Raaphorst, Joost |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335467/ https://www.ncbi.nlm.nih.gov/pubmed/37429682 http://dx.doi.org/10.1136/bmjopen-2022-067435 |
Ejemplares similares
-
B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies
por: Anang, Dornatien C, et al.
Publicado: (2022) -
Assessment of disability in idiopathic inflammatory myopathy: a call for linearity
por: Min, Minoesch, et al.
Publicado: (2021) -
Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review
por: Kamperman, Renske G., et al.
Publicado: (2022) -
Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study
por: Lim, Johan, et al.
Publicado: (2020) -
Perceived Drivers and Barriers to the Adoption of eMental Health by Psychologists: The Construction of the Levels of Adoption of eMental Health Model
por: Feijt, Milou A, et al.
Publicado: (2018)